{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000096","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.583435+00:00","generated_at":"2026-06-13T07:42:15.348450+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Caribou Biosciences prices upsized $125M public offering at $6.50/sh","bullets":["Priced 19,230,769 shares at $6.50 per share; underwriters granted 30-day option for 2,884,615 additional shares.","Gross proceeds ~$125M; net proceeds to Caribou expected ~$116.9M after discounts and expenses.","Offering expected to close on or about July 18, 2023; BofA, Leerink, Evercore, RBC as book-runners.","All shares sold by Caribou; proceeds for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000096","json":"https://secwatch.observer/filing/0001619856-23-000096.json","markdown":"https://secwatch.observer/filing/0001619856-23-000096.md","text":"https://secwatch.observer/filing/0001619856-23-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000096/0001619856-23-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000096/crbu-20230713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:42:15.348450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17a87f04946cc8f6465a154d9b2ae60d92ec5607","claim":"Caribou Biosciences, Inc. entered into Underwriting Agreement with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters (effective 2023-07-13).","evidence_excerpt":"On July 13, 2023, Caribou Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 19,230,769 shares of its common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000096/0001619856-23-000096-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters"},{"label":"Effective","value":"2023-07-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}